Tumor immunology: The glass is half full

Immunity

Volumn 9, Issue 6, 1998, Pages 757-763

  Sogn, John A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RESEARCH; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY; TUMOR IMMUNOLOGY;

EID: 0032425063     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-7613(00)80641-X     Document Type: Review

References (74)

1. + T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J Exp. Med. 187, 1555-1564.
2. Arai, H., Gordon, D., Nabel, E.G., and Nabel, G.J. (1997). Gene transfer of Fas ligand induces tumor regression in vivo. Proc. Natl. Acad. Sci. USA 94, 13862-13867.
3. Armstrong, T.D., Pulaski, B.A., and Ostrand-Rosenberg, S. (1998). Tumor antigen presentation: changing the rules. Cancer Immunol. Immunother. 46, 70-74.
4. Banchereau, J., and Steinman, R.M. (1998). Dendritic cells and the control of immunity. Nature 392, 245-252.
5. Barrett, A.J. (1997). Mechanisms of the graft-versus-leukemia reaction. Stem Cells 15, 248-258.
6. Birkeland, S.A., Storm, H.H., Lamm, L.U., Barlow, L., Blohme, I., Forsberg, B., Eklund, B., Fjeldborg, O., Friedberg, M., Frödin, L., et al. (1995). Cancer risk after renal transplantation in the nordic countries, 1964-1986. Int. J. Cancer 60, 183-189.
7. Boon, T., and Old, L.J. (1997). Cancer tumor antigens. Curr. Opin. Immunol. 9, 681-683.
8. Burnet, F.M. (1970). The concept of immunological surveillance. Prog. Exp. Tumor Res. 13, 1-27.
9. Cheever, M.A., and Chen, W. (1997). Therapy with T cells: principles revisited, Immunol. Rev. 157, 177-194.
10. Chen, L., Ashe, S., Brady, W.A., Hellström, I., Hellström, K.E., Ledbetter, J.A., McGowan, P., and Linsley, P.S. (1992). Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71, 1093-1102.
11. Chouaib, S., Asselin-Paturel, C., Mami-Chouaib, F., Caignard, A., and Blay, J.Y. (1997). The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol. Today 18, 493-497.
12. Clerici, M., Shearer, G.M., and Clerici, E. (1998). Cytokine dysregulation in invasive cervical carcinoma and other human neoplasias: time to consider the TH1/TH2 paradigm. J. Natl. Cancer Inst. 90, 261-263.
13. Colombo, M.P., and Forni, G. (1997). Immunotherapy I: cytokine gene transfer strategies. Cancer Metastasis Rev. 16, 421-432.
14. Correa, M.R., Ochoa, A.C., Ghosh, P., Mizoguchi, H., Harvey, L., and Longo, D.L. (1997). Sequential development of structural and functional alterations in T cells from tumor-bearing mice. J. Immunol. 158, 5292-5296.
15. Dimitriadou, V., and Koutsilieris, M. (1997). Mast cell-tumor cell interactions: for or against tumour growth and metastasis? Anticancer Res. 17, 1541-1550.
16. Dong, Z., Kumar, R., Yang, X., and Fidler, I.J. (1997). Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88, 801-810.
17. Faure, F., Even, J., and Kourilsky, P. (1998). Tumor-specific immune response: current in vitro analyses may not reflect the in vivo immune status. Crit. Rev. Immunol. 18, 77-86.
18. Fenton, R.G., and Longo, D.L. (1997). Danger versus tolerance: paradigms for future studies of tumor-specific cytotoxic T lymphocytes. J. Natl. Cancer Inst. 89, 272-275.
19. Franco, J.L., Ghosh, P., Wiltrout, R.H., Carter, C.R., Zea, A.H., Momozaki, N., Ochoa, A.C., Longo, D.L., Sayers, T.J., and Komschlies, K.L. (1995). Partial degradation of T-cell signal transduction molecules by contaminating granulocytes during protein extraction of splenic T cells from tumor-bearing mice. Cancer Res. 55, 3840-3846.
20. Fuchs, E.J., and Matzinger, P. (1996). Is cancer dangerous to the immune system? Semin. Immunol. 8, 271-280.
21. Garrido, F., Ruiz-Cabello, F., Cabrera, T., Pérez-Villar, J.J., López-Botet, M., Duggan-Keen, M., and Stern, P.L. (1997). Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 18, 89-95.
22. Green, D.R., and Ware, C.F. (1997). Fas-ligand: privilege and peril. Proc. Natl. Acad. Sci. USA 94, 5986-5990.
23. Hahne, M., Rimoldi, D., Schröter, M., Romero, P., Schreier, M., French, L.E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., et al. (1996). Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 274, 1363-1366.
24. Hara, I., Takechi, Y., and Houghton, A.N. (1995). Implicating a role for immune recognition of self in tumor rejection: passive immunization against the Brown locus protein. J. Exp. Med. 182, 1609-1614.
25. Hellström, I., and Hellström, K.E. (1998). T cell immunity to tumor antigens. Crit. Rev. Immunol. 18, 1-6.
26. Hsu, F.J., Caspar, C.B., Czerwinski, D., Kwak, L.W., Liles, T.M., Syrengelas, A., Taidi-Laskowski, B., and Levy, R. (1997). Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood 89, 3129-3135.
27. Huang, A.Y.C., Bruce, A.T., Pardoll, D.M., and Levitsky, H.I. (1996). Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med. 183, 769-776.
28. Kaminski, M.S., Zasadny, K.R., Francis, I.R., Fenner, M.C., Ross, C.W., Milik, A.W., Estes, J., Tuck, M., Regan, D., Fisher, S., et al. (1996). Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol. 14, 1974-1981.
29. Kaplan, D.H., Dighe, A.S., Shankaran, V., Old, L.J., and Schreiber, R.D. (1998). Demonstration of an IFNγ dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95, 7556-7561.
30. Kirsch, I.R., and Lista, F. (1997). Lymphocyte-specific genomic instability and risk of lymphoid malignancy. Semin. Immunol. 9, 207-215.
31. Klein, G. (1975). Immunological surveillance against neoplasia. Harvey Lect. 69, 71-102.
32. Kolb, H.-J., and Holler, E. (1997). Adoptive immunotherapy with donor lymphocyte transfusions. Curr. Opin. Oncol. 9, 139-145.
33. Kolenko, V., Wang, Q., Riedy, M.C., O'Shea, J., Ritz, J., Cathcart, M.K., Rayman, P., Tubbs, R., Edinger, M., Novick, A., et al. (1997). Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling. J. Immunol. 159, 3057-3067.
34. Kündig, T.M., Bachmann, M.F., DiPaolo, C., Simard, J.J.L., Battegay, M., Lother, H., Gessner, A., Kühlke, K., Ohashi, P.S., Hengartner, H., and Zinkernagel, R.M. (1995). Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 268, 1343-1347.
35. Lala, P.K. (1998). Significance of nitric oxide in carcinogenesis, tumor progression and cancer therapy. Cancer Metastasis Rev. 17, 1-6.
36. Levey, D.L., and Srivastava, P.K. (1996). Alterations of T cells of cancer-bearers: whence specificity? Immunol. Today 17, 365-368.
37. Ling, W., Rayman, P., Uzzo, R., Clark, P., Kim, H.J., Tubbs, R., Novick, A., Bukowski, R., Hamilton, T., and Finke, J. (1998). Impaired activation of NFκB in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, IκBα. Blood 92, 1334-1341.
38. Liu, S.Y., and Press, O.W. (1997). The potential for immunoconjugates in lymphoma therapy. Hematol. Oncol. Clin. North Am. 11, 987-1006.
39. Liu, B., Podack, E.R., Allison, J.P., and Malek, T.R. (1996). Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors. J. Immunol. 156, 1117-1125.
40. Maloney, D.G., Grillo-Lopez, A.J., White, C.A., Bodkin, D., Schilder, R.J., Neidhart, J.A., Janakiraman, N., Foon, K.A., Liles, T.-M., Dallaire, B.K., et al. (1997). IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90, 2188-2195.
41. Marchand, M., Weynants, P., Rankin, E., Arienti, F., Belli, F., Parmiani, G., Cascinelli, N., Bourlond, A., Vanwijck, R., Humblet, Y., et al. (1995). Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer 63, 883-885.
42. Maric, M., Zheng, P., Sarma, S., Guo, Y., and Liu, Y. (1998). Maturation of cytotoxic T lymphocytes against a B7-transfected nonmetastatic tumor: a critical role for costimulation by B7 on both tumor and host antigen-presenting cells. Cancer Res. 58, 3376-3384.
43. Matzinger, P. (1994). Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991-1045.
44. Melero, I., Bach, N., and Chen, L. (1997). Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens. Life Sci. 60, 2035-2041.
45. Miescher, S., Whiteside, T.L., Carrel, S., and von Fliedner, V. (1986). Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J. Immunol. 136, 1899-1907.
46. Mizoguchi, H., O'Shea, J.J., Longo, D.L., Loeffler, C.M., McVicar, D.W., and Ochoa, A.C. (1992). Alteration of signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258, 1795-1798.
47. Morgan, D.J., Kreuwel, H.T.C., Fleck, S., Levitsky, H.I., Pardoll, D.M., and Sherman, L.A. (1998). Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160, 643-651.
48. Musiani, P., Modesti, A., Giovarelli, M., Cavallo, F., Colombo, M.P., Lollini, P.L., and Forni, G. (1997). Cytokines, tumour-cell death and immunogenicity: a question of choice. Immunol. Today 18, 32-36.
49. Nanda, N.K., and Sercarz, E.E. (1995). Induction of anti-self-immunity to cure cancer. Cell 82, 13-17.
50. Nieland, J.D., Loviscek, K., Kono, K., Albain, K.S., McCall, A.R., Potkul, R.K., Fisher, S.G., Velders, M.P., Petersson, M., Kiessling, R., and Kast, W.M. (1998). PBLs of early breast carcinoma patients with a high nuclear grade tumor unlike PBLs of cervical carcinoma patients do not show a decreased TCRζ expression but are functionally impaired. J. Immunother. 21, 317-322.
51. Onrust, S.V., Hartl, P.M., Rosen, S.D., and Hanahan, D. (1996). Modulation of L-selectin ligand expression during an immune response accompanying tumorigenesis in transgenic mice. J. Clin. Invest. 97, 54-64.
52. Pekarek, L.A., Starr, B.A., Toledano, A.Y., and Schreiber, H. (1995). Inhibition of tumor growth by elimination of granulocytes. J. Exp. Med. 181, 435-440.
53. Penninger, J.M., Wen, T., Timms, E., Potter, J., Wallace, V.A., Matsuyama, T., Ferrick, D., Sydora, B., Kronenberg, M., and Mak, T.W. (1995). Spontaneous resistance to acute T-cell leukaemias in TCRVγ1.1Jγ4Cγ4 transgenic mice. Nature 375, 241-244.
54. Petersson, M., Charo, J., Salazar-Onfray, F., Noffz, G., Mohaupt, M., Qin, Z., Klein, G., Blankenstein, T., and Kiessling, R. (1998). Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J. Immunol. 161, 2099-2105.
55. Ratliff, T.L. (1992). Role of the immune response in BCG for bladder cancer. Eur. Urol. 21, suppl. 2, 17-21.
56. Reichert, T.E., Rabinowich, H., Johnson, J.T., and Whiteside, T.L. (1998). Mechanisms responsible for signaling and functional defects. J. Immunother. 21, 295-306.
57. Riethmüller, G., Holz, E., Schlimok, G., Schmiegel, W., Raab, R., Höffken, K., Gruber, R., Funke, I., Pichlmaier, H., Hirche, H., et al. (1998). Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J. Clin. Oncol. 16, 1788-1794.
58. Schuler, G., and Steinman, R.M. (1997). Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. 186, 1183-1187.
59. Seliger, B., Maeurer, M.J., and Ferrone, S. (1997). TAP off - tumors on. Immunol. Today 18, 292-299.
60. Singh, S., Ross, S.R., Acena, M., Rowley, D.A., and Schreiber, H. (1992). Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med. 175, 139-146.
61. Speiser, D.E., and Ohashi, P.S. (1998). Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. Cell. Mol. Life Sci. 54, 263-271.
62. Speiser, D.E., Miranda, R., Zakarian, A., Bachmann, M.F., McKall-Faienza, K., Odermatt, B., Hanahan, D., Zinkernagel, R.M., and Ohashi, P.S. (1997). Activation of cytotoxic T cells by solid tumours? J. Exp. Med. 186, 645-653.
63. Srivastava, P.K., Menoret, A., Basu, S., Binder, R.J., and McQuade, K.L. (1998). Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity 8, 657-665.
64. Staveley-O'Carroll, K., Sotomayor, E., Montgomery, J., Borrello, I., Hwang, L., Fein, S., Pardoll, D., and Levitsky, H. (1998). Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95, 1178-1183.
65. Toes, R.E.M., Blom, R.J.J., Offringa, R., Kast, W.M., and Melief, C.J.M. (1996). Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 156, 3911-3918.
66. Umansky, V., Schirrmacher, V., and Rocha, M. (1996). New insights into tumor-host interactions in lymphocyte metastasis. J. Mol. Med. 74, 353-363.
67. Uyttenhove, C., Maryanski, J., and Boon, T. (1983). Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med. 157, 1040-1052.
68. Van den Eynde, B.J., and van der Bruggen, P. (1997). T cell defined tumor antigens. Curr. Opin. Immunol. 9, 684-693.
69. Vierboom, M.P.M., Nijman, H.W., Offringa, R., van derVoort, E.I.H., van Hall, T., van der Broek, L., Fleuren, G.J., Kenemans, P., Kast, W.M., and Melief, C.J.M. (1997). Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med. 186, 695-704.
70. Wick, M., Dubey, P., Koeppen, H., Siegel, C.T., Fields, P.E., Chen, L., Bluestone, J.A., and Schreiber, H. (1997). Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med. 186, 229-238.
71. Wiedenfeld, E.A., Fernandez-Viña, M., Berzofsky, J.A., and Carbone, D.P. (1994). Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A*0201 peptide consensus motif. Cancer Res. 54, 1175-1177.
72. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281-1284.
73. Xiang, R., Lode, H.N., Dreier, T., Gillies, S.D., and Reisfeld, R.A. (1998). Induction of persistent tumor-specific immunity in mice cured of established colon carcinoma metastases. Cancer Res. 58, 3918-3925.
74. Yee, C., Riddell, S.R., and Greenberg, P.D. (1997). Prospects for adoptive T cell therapy. Curr. Opin. Immunol. 9, 702-708.